deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03638830

Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

Randomized, Blind, Placebo-controlled Study to Evaluate Safety and Efficacy of Ftortiazinon in Combination With Maxipime®, in Comparison With Placebo in Combination With Maxipime®, in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

Sponsor: Acellena Contract Drug Research and Development

Updated 12 times since 2018 Last updated: Jun 17, 2025 Started: Oct 17, 2018 Primary completion: Nov 23, 2022 Completion: Nov 23, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa and Pseudomonas Aeruginosa, this trial is completed. The trial is conducted by Acellena Contract Drug Research and Development and has accumulated 12 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshotNot Yet Recruiting~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshotRecruiting~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshotRecruiting~Feb 2019 – ~Dec 2019 · 10 months · monthly snapshotRecruiting~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotRecruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotRecruiting~Feb 2021 – ~Feb 2023 · 24 months · monthly snapshotRecruiting~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotUnknown~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: UnknownCompleted

  3. Sep 2024 — Jul 2025 [monthly]

    Unknown PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

  5. Feb 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: RecruitingUnknown Status

Show 7 earlier versions
  1. Feb 2021 — Feb 2023 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  3. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Feb 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  5. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  6. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  7. Sep 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acellena Contract Drug Research and Development
  • Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Data source: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

For direct contact, visit the study record on ClinicalTrials.gov .